BMY Q4 2019 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q4 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$7.9B+33.0% YoY

Gross Profit

$4.4B55.6% margin

Operating Income

$701M8.8% margin

Net Income

-$1.1B-13.3% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+32.3%

Cash Flow

Operating Cash Flow

$2.0B

Free Cash Flow

$1.8B

Stock-Based Comp.

$284M

Balance Sheet

Total Assets

$129.9B

Total Liabilities

$78.2B

Stockholders' Equity

$51.6B

Cash & Equivalents

$12.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7.9B	$6.0B	+33.0%
Gross Profit	$4.4B	$4.3B	+3.0%
Operating Income	$701M	$1.6B	-55.9%
Net Income	-$1.1B	$1.2B	-191.0%

Revenue Segments

Eliquis

$2.0B33%

Opdivo

$1.8B29%

Orencia

$792M13%

Sprycel

$549M9%

Yervoy

$385M6%

Mature Products And All Other

$356M6%

Baraclude

$122M2%

Empliciti

$94M2%

Geographic Segments

UNITED STATES

$4.8B60%

Europe

$1.9B23%

Rest Of World

$1.2B15%

Other Region

$166M2%